BAY2287411, a thorium-227-labeled antibody-chelator conjugate, was administered to patients with tumors known to express MSLN to evaluate the safety, tolerability, maximum tolerated dose, PK, anti-tumor activity and recommended dose for further clinical development (NCT03507452). This evidence concerns the gene MSLN and neoplasm.